Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.

Journal of receptor and signal transduction research - 1 Feb 2018

Bommu Uma Devi, Konidala Kranthi Kumar, Pamanji Rishika, Yeguvapalli Suneetha

Abstract excerpt

The observable mutated isoforms of epidermal growth factor receptor (EGFR) are important considerable therapeutic benchmarks in moderating the non-small cell lung cancer (NSCLC). Recently, quinazoline-based ATP competitive inhibitors have been developed against the EGFR; however, these imply the mutation probabilities, which contribute to the discovery of high probable novel inhibitors for EGFR mutants....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Ligands

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 29369008
DOI: 10.1080/10799893.2018.1426603

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.PMID 29369008Read ↗

Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity.Semantic proximity Read ↗

QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.Semantic proximity Read ↗

Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).Semantic proximity Read ↗

Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer.Semantic proximity Read ↗

In silico target specific design of potential quinazoline-based anti-NSCLC agents.Semantic proximity Read ↗

Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.Semantic proximity Read ↗

Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites.Semantic proximity Read ↗

Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.Semantic proximity Read ↗

Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.Semantic proximity Read ↗

Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.Semantic proximity Read ↗

Toward structure-based drug design against the epidermal growth factor receptor (EGFR).Semantic proximity Read ↗

In silico screening of novel designed series of pyrazolidine compounds targeting Epidermal Growth Factor ReceptorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.